Interim data from a retrospective multicenter European study presented in the PET RANO program suggest that amino acid PET (PET RANO 1.0) detects early metabolic response to vorasidenib earlier than structural MRI-based RANO 2.0 criteria in IDH-mutant glioma. Serial imaging captured treatment effects before radiographic change, addressing a core timing limitation in standard response assessment. Among 50 patients, partial response was documented in 29% using PET RANO 1.0 versus 6% under RANO 2.0. Median time to response was 4 months (range 1 to 14) with PET RANO 1.0 compared with 8 months (range 1 to 11) on RANO 2.0, while stable disease rates differed accordingly (62% vs 74%). The classification signal was dominated by change in metabolic tumor volume, ranging from complete metabolic resolution to large increases consistent with progression. Lead author Sophie E.M. Veldhuijzen van Zanten (Erasmus MC) highlighted the clinical rationale: structural MRI tumor volume can change slowly under treatment, so earlier metabolic readouts may improve response timing. The practical implication is that PET-based criteria may enable earlier treatment signals in ongoing and future vorasidenib studies in IDH-mutant disease, pending broader validation.
Get the Daily Brief